

---

---

**A BILL FOR AN ACT**

RELATING TO THE UNIFORM CONTROLLED SUBSTANCE ACT.

**BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:**

1 SECTION 1. Section 329-14, Hawaii Revised Statutes, is  
2 amended as follows:

3 1. By amending subsection (b) to read:

4 "(b) Any of the following opiates, including their  
5 isomers, esters, ethers, salts, and salts of isomers, esters,  
6 and ethers, unless specifically excepted, whenever the existence  
7 of these isomers, esters, ethers, and salts is possible within  
8 the specific chemical designation:

- 9 (1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-  
10 phenethyl)-4-piperidinyl]-N-phenylacetamide);  
11 (2) Acetylmethadol;  
12 (3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-  
13 phenylacetamide), its optical, positional, and  
14 geometric isomers, salts, and salts of isomers;  
15 (4) Acryl fentanyl [N-(1-phenethylpiperidin-4-yl)-N-  
16 phenylacrylamide] (Other name: acryloylfentanyl);  
17 (5) AH-7921 (3,4-dichloro-N-[(1-  
18 dimethylamino)cyclohexylmethyl]benzamide);

H.B. NO. 1133

- 1 (6) Allylprodine;
- 2 (7) Alphacetylmethadol (except levo-alphacetylmethadol,  
3 levomethadyl acetate, or LAAM);
- 4 (8) Alphameprodine;
- 5 (9) Alphamethadol;
- 6 (10) Alpha'-methyl butyryl fentanyl (2-methyl-N-(1-  
7 phenethylpiperidin-4-yl)-N-phenylbutanamide);
- 8 [~~(10)~~] (11) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-  
9 phenyl)ethyl-4-piperidyl]propionanilide; 1-(1-methyl-  
10 2-phenylethyl)-4-(N-propanilido)piperidine);
- 11 [~~(11)~~] (12) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-  
12 thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
- 13 [~~(12)~~] (13) Benzethidine;
- 14 [~~(13)~~] (14) Benzylfentanyl (N-[1-benzyl-4-piperidyl]-N-  
15 phenylpropanamide), its optical isomers, salts, and  
16 salts of isomers;
- 17 [~~(14)~~] (15) Betacetylmethadol;
- 18 [~~(15)~~] (16) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-  
19 phenethyl)-4-piperidinyl]-N-phenylpropanamide);
- 20 [~~(16)~~] (17) Beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-  
21 2-phenethyl)-3-methyl-4-piperidinyl]-N-  
22 phenylpropanamide);





H.B. NO. 1133

- 1 fluorophenyl)propionamide) (Other name: 2'-fluoro 2-
- 2 fluorofentanyl);
- 3 [~~(41)~~] (45) Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-
- 4 N-phenylfuran-2-carboxamide);
- 5 (46) 3-furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
- 6 phenylfuran-3-carboxamide);
- 7 [~~(42)~~] (47) Furethidine;
- 8 [~~(43)~~] (48) Hydroxypethidine;
- 9 (49) Isovaleryl fentanyl (3-methyl-N-(1-phenethylpiperidin-
- 10 4-yl)-N-phenylbutanamide);
- 11 [~~(44)~~] (50) Ketobemidone;
- 12 [~~(45)~~] (51) Levomoramide;
- 13 [~~(46)~~] (52) Levophenacylmorphan;
- 14 (53) Meta-fluorofentanyl (N-(3-fluorophenyl)-N-(1-
- 15 phenethylpiperidin-4-yl)propionamide);
- 16 (54) Meta-fluoroisobutyryl fentanyl (N-(3-fluorophenyl)-N-
- 17 (1-phenethylpiperidin-4-yl)isobutyramide);
- 18 [~~(47)~~] (55) Methoxyacetyl fentanyl (2-methoxy-N-(1-
- 19 phenethylpiperidin-4-yl)-N-phenylacetamide);
- 20 (56) 2-Methyl AP-237 (1-(2-methyl-4-(3-phenylprop-2-en-1-
- 21 yl)piperazin-1-yl)butan-1-one);

H.B. NO. 1133

- 1        (57) Metonitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-5-  
2        nitro-1H-benzimidazol-1-yl)ethan-1-amine);
- 3        [~~(48)~~] (58) 4'-methyl acetyl fentanyl (N-(1-(4-  
4        methylphenethyl)piperidin-4-yl)-N-phenylacetamide);
- 5        [~~(49)~~] (59) 3-methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-  
6        4-piperidyl]-N-phenylpropanamide);
- 7        [~~(50)~~] (60) 3-methylthiofentanyl (N-[3-methyl-1-(2-  
8        thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
- 9        [~~(51)~~] (61) Morpheridine;
- 10       [~~(52)~~] (62) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
- 11       (63) N,N-diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1H-  
12       benzimidazol-1-yl)ethan-1-amine (other name:  
13       protonitazene);
- 14       (64) N-pyrrolidino etonitazene (2-(4-ethoxybenzyl)-5-nitro-  
15       1(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole) (other  
16       name: etonitazepyne);
- 17       [~~(53)~~] (65) Noracymethadol;
- 18       [~~(54)~~] (66) Norlevorphanol;
- 19       [~~(55)~~] (67) Normethadone;
- 20       [~~(56)~~] (68) Norpipanone;
- 21       [~~(57)~~] (69) Ocfentanil [N-(2-fluorophenyl)-2-methoxy-N-(1-  
22       phenethylpiperidin-4-yl)acetamide];

H.B. NO. 1133

- 1        [~~58~~] (70) Ortho-fluoroacryl fentanyl (N-(2-fluorophenyl)-  
2                    N-(1-phenethylpiperidin-4-yl)acrylamide);
- 3        [~~59~~] (71) Ortho-fluorobutyryl fentanyl (N-(2-  
4                    fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide)  
5                    (Other name: 2-fluorobutyryl fentanyl);
- 6        (72) Ortho-fluorofuranyl fentanyl (N-(2-fluorophenyl)-N-(1-  
7                    phenethylpiperidin-4-yl)furan-2-carboxamide);
- 8        [~~60~~] (73) Ortho-fluorofentanyl (N-(2-fluorophenyl)-N-(1-  
9                    phenethylpiperidin-4-yl)propionamide) (Other name: 2-  
10                    fluorofentanyl);
- 11       [~~61~~] (74) Ortho-fluoroisobutyryl fentanyl (N-(2-  
12                    fluorophenyl)-N-(1-phenethylpiperidin-4-  
13                    yl)isobutyramide);
- 14       [~~62~~] (75) Ortho-methyl acetylfentanyl (N-(2-methylphenyl)-  
15                    N-(1-phenethylpiperidin-4-yl)acetamide) (Other  
16                    name: 2-methyl acetylfentanyl);
- 17       [~~63~~] (76) Ortho-methyl methoxyacetyl fentanyl (2-methoxy-  
18                    N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-  
19                    yl)acetamide) (Other name: 2-methyl methoxyacetyl  
20                    fentanyl);
- 21       [~~64~~] (77) Para-fluorobutyryl fentanyl (N-(4-fluorophenyl)-  
22                    N-(1-phenethylpiperidin-4-yl)butyramide);



H.B. NO. 1133

- 1        [~~76~~] (91) Properidine;  
2        [~~77~~] (92) Propiram;  
3        [~~78~~] (93) Racemoramide;  
4        [~~79~~] (94) Thenylfentanyl (N-[1-(2-thienyl)methyl-4-  
5                piperidyl]-N-phenylpropanamide), its optical isomers,  
6                salts, and salts of isomers;  
7        [~~80~~] (95) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-  
8                piperidinyl]-propanamide);  
9        [~~81~~] (96) Thiofuranyl fentanyl (N-(1-phenethylpiperidin-4-  
10                yl)-N-phenylthiophene-2-carboxamide) (Other names: 2-  
11                thiofuranyl fentanyl; thiophene fentanyl);  
12        [~~82~~] (97) Tilidine;  
13        [~~83~~] (98) Trimeperidine; and  
14        [~~84~~] (99) U-47700 (3,4-dichloro-N-[2-  
15                (dimethylamino)cyclohexyl]-N-methylbenzamide."

16        2. By amending subsection (d) to read:

17        "(d) Hallucinogenic substances. Unless specifically  
18        excepted or unless listed in another schedule, any material,  
19        compound, mixture, or preparation that contains any quantity of  
20        the following hallucinogenic substances, including their salts,  
21        isomers, and salts of isomers, whenever the existence of these

H.B. NO. 1133

1 salts, isomers, and salts of isomers is possible within the  
2 specific chemical designation:

- 3 (1) Alpha-ethyltryptamine (AET);
- 4 (2) 2,5-dimethoxy-4-ethylamphetamine (DOET);
- 5 (3) 2,5-dimethoxyamphetamine (2,5-DMA);
- 6 (4) 3,4-methylenedioxy amphetamine;
- 7 (5) 3,4-methylenedioxymethamphetamine (MDMA);
- 8 (6) N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy-  
9 MDA);
- 10 (7) 3,4-methylenedioxy-N-ethylamphetamine (MDE);
- 11 (8) 5-methoxy-3,4-methylenedioxy-amphetamine;
- 12 (9) 4-bromo-2,5-dimethoxy-amphetamine (4-bromo-2,5-DMA);
- 13 (10) 4-Bromo-2,5-dimethoxyphenethylamine (Nexus);
- 14 (11) 3,4,5-trimethoxy amphetamine;
- 15 (12) Bufotenine;
- 16 (13) 4-methoxyamphetamine (PMA);
- 17 (14) Diethyltryptamine;
- 18 (15) Dimethyltryptamine;
- 19 (16) 4-methyl-2,5-dimethoxy-amphetamine;
- 20 (17) Gamma hydroxybutyrate (GHB) (some other names include  
21 gamma hydroxybutyric acid; 4-hydroxybutyrate; 4-

H.B. NO. 1133

- 1 hydroxybutanoic acid; sodium oxybate; sodium  
2 oxybutyrate);
- 3 (18) Ibogaine;
- 4 (19) Lysergic acid diethylamide;
- 5 (20) Marijuana;
- 6 (21) Parahexyl;
- 7 (22) Mescaline;
- 8 (23) Peyote;
- 9 (24) N-ethyl-3-piperidyl benzilate;
- 10 (25) N-methyl-3-piperidyl benzilate;
- 11 (26) Psilocybin;
- 12 (27) Psilocyn;
- 13 (28) 1-[1-(2-Thienyl) cyclohexyl] Pyrrolidine (TCPy);
- 14 (29) Ethylamine analog of phencyclidine (PCE);
- 15 (30) Pyrrolidine analog of phencyclidine (PCPy, PHP);
- 16 (31) Thiophene analog of phencyclidine (TPCP; TCP);
- 17 (32) Gamma-butyrolactone, including butyrolactone;
- 18 butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone
- 19 dihydro; dihydro-2(3H)furanone; tetrahydro-2-furanone;
- 20 1,2-butanolide; 1,4-butanolide; 4-butanolide; gamma-
- 21 hydroxybutyric acid lactone; 3-hydroxybutyric acid
- 22 lactone and 4-hydroxybutanoic acid lactone with

H.B. NO. 1133

- 1 Chemical Abstract Service number 96-48-0 when any such  
2 substance is intended for human ingestion;
- 3 (33) 1,4 butanediol, including butanediol; butane-1,4-diol;  
4 1,4- butylenes glycol; butylene glycol; 1,4-  
5 dihydroxybutane; 1,4- tetramethylene glycol;  
6 tetramethylene glycol; tetramethylene 1,4- diol with  
7 Chemical Abstract Service number 110-63-4 when any  
8 such substance is intended for human ingestion;
- 9 (34) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7),  
10 its optical isomers, salts, and salts of isomers;
- 11 (35) N-benzylpiperazine (BZP; 1-benzylpiperazine), its  
12 optical isomers, salts, and salts of isomers;
- 13 (36) 1-(3-trifluoromethylphenyl)piperazine (TFMPP), its  
14 optical isomers, salts, and salts of isomers;
- 15 (37) Alpha-methyltryptamine (AMT);
- 16 (38) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);
- 17 (39) Salvia divinorum;
- 18 (40) Salvinorin A;
- 19 (41) Divinorin A;
- 20 (42) 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DIPT) (some  
21 trade or other names: 5-methoxy-3-[2-  
22 (dimethylamino)ethyl]indole; 5-MeO-DMT);

H.B. NO. 1133

- 1 (43) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);
- 2 (44) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);
- 3 (45) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);
- 4 (46) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);
- 5 (47) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-
- 6 2);
- 7 (48) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine
- 8 (2C-T-4);
- 9 (49) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
- 10 (50) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);
- 11 (51) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);
- 12 (52) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-
- 13 methoxybenzyl)ethanamine, its optical, positional, and
- 14 geometric isomers, salts, and salts of isomers (Other
- 15 names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5);
- 16 (53) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-
- 17 methoxybenzyl)ethanamine, its optical, positional, and
- 18 geometric isomers, salts, and salts of isomers (Other
- 19 names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82);
- 20 (54) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-
- 21 methoxybenzyl)ethanamine, its optical, positional, and

H.B. NO. 1133

- 1           geometric isomers, salts, and salts of isomers (Other  
2           names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36);
- 3       (55) N-ethylhexedrone, its optical, positional, and  
4           geometric isomers, salts, and salts of isomers (Other  
5           names: [alpha]-ethylaminohexanophenone; 2-  
6           (ethylamino)-1-phenylhexan-1-one);
- 7       (56) Alpha-pyrrolidinohexanophenone, its optical,  
8           positional, and geometric isomers, salts, and salts of  
9           isomers (Other names: [alpha]-PHP; [alpha]-  
10          pyrrolidinohexanophenone; 1-phenyl-2-(pyrrolidin-1-  
11          yl)hexan-1-one);
- 12       (57) 4-methyl-alpha-ethylaminopentiophenone, its optical,  
13          positional, and geometric isomers, salts, and salts of  
14          isomers (Other names: 4-MEAP; 2-(ethylamino)-1-(4-  
15          methylphenyl)pentan-1-one);
- 16       (58) 4'-methyl-alpha-pyrrolidinohexiophenone, its optical,  
17          positional, and geometric isomers, salts, and salts of  
18          isomers (Other names: MPHP; 4'-methyl-alpha-  
19          pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-  
20          (pyrrolidin-1-yl)hexan-1-one);
- 21       (59) Alpha-pyrrolidinoheptaphenone, its optical,  
22          positional, and geometric isomers, salts, and salts of

- 1 isomers (Other names: PV8; 1-phenyl-2-(pyrrolidin-1-  
2 yl)heptan-1-one);
- 3 (60) 4'-chloro-alpha-pyrrolidinovalerophenone, its optical,  
4 positional, and geometric isomers, salts, and salts of  
5 isomers (Other names: 4-chloro-[alpha]-PVP; 4'-  
6 chloro-[alpha]-pyrrolidinopentiophenone; 1-(4-  
7 chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one); [~~and~~]
- 8 (61) 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one  
9 (methoxetamine, MXE) [~~-~~];
- 10 (62) Eutylone (1-(1,3-benzodioxol-5-yl)-2-  
11 (ethylamino)butan-1-one) (other name: bk-EBDB); and
- 12 (63) Zipeprol (1-methoxy-3[-4-(2-methoxy-2-  
13 phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol),  
14 including its isomers, esters, ethers, salts, and  
15 salts of isomers, esters and ethers, whenever the  
16 existence of such isomers, esters, ethers and salts is  
17 possible within the specific chemical designation."
- 18 3. By amending subsection (f) to read:
- 19 "(f) Stimulants. Unless specifically excepted or unless  
20 listed in another schedule, any material, compound, mixture, or  
21 preparation that contains any quantity of the following

H.B. NO. 1133

1 substances having a stimulant effect on the central nervous  
2 system, including its salts, isomers, and salts of isomers:

3 (1) Amineptine;

4 [~~(1)~~] (2) Aminorex;

5 [~~(2)~~] (3) Cathinone;

6 [~~(3)~~] (4) 4,4'-dimethylaminorex (common name: 4,4'-DMAR);

7 [~~(4)~~] (5) Fenethylamine;

8 (6) Mesocarb (chemical name: N-phenyl-N'-(3-(1-

9 phenylpropan-2-yl)-1,2,3-oxadiazol-3-ium-5-

10 yl)carbamimidate);

11 [~~(5)~~] (7) Methcathinone;

12 (8) Methiopropamine (N-methyl-1-(thiophen-2-yl)propan-2-

13 amine);

14 [~~(6)~~] (9) 4-methylaminorex;

15 [~~(7)~~] (10) N-ethylamphetamine;

16 [~~(8)~~] (11) N,N-dimethylamphetamine;

17 [~~(9)~~] (12) Substituted cathinones, any compound, except

18 bupropion or compounds listed under a different

19 schedule, structurally derived from 2-aminopropan-1-

20 one by substitution at the 1-position with either

21 phenyl, naphthyl, or thiophene ring systems, whether

H.B. NO. 1133

1 or not the compound is further modified in any of the  
2 following ways:

3 (A) By substitution in the ring system to any extent  
4 with alkyl, alkylendioxy, alkoxy, haloalkyl,  
5 hydroxyl, or halide substituents, whether or not  
6 further substituted in the ring system by one or  
7 more other univalent substituents;

8 (B) By substitution at the 3-position with an acyclic  
9 alkyl substituent; or

10 (C) By substitution at the 2-amino nitrogen atom with  
11 alkyl, dialkyl, benzyl, or methoxybenzyl groups,  
12 or by inclusion of the 2-amino nitrogen atom in a  
13 cyclic structure.

14 Some other trade names: Mephedrone (2-methylamino-1-p-  
15 tolylpropan-1-one), also known as 4-  
16 methylmethcathinone (4-MMC), methylephedrone or MMCA;  
17 Methylenedioxyprovalerone (MDPV, MDPK); methylone or  
18 3,4-methylenedioxy-methcathinone; and 1-  
19 (benzo[d][1,3]dioxol-5-yl)-2-(ethylamino)propan-1-one,  
20 monohydrochloride, also known as Ethylone, bk-MDEA  
21 hydrochloride, MDEC; 3,4-Methylenedioxy-N-  
22 ethylcathinone; bk-Methylenedioxyethylamphetamine, 4-

H.B. NO. 1133

1 methyl-N-ethylcathinone (4-MEC); 4-methyl-alpha-  
2 pyrrolidinopropiophenone (4-MePPP); alpha-  
3 pyrrolidinopentiophenone ([alpha]-PVP); 1-(1,3-  
4 benzodioxol-5-yl)-2-(methylamino)butan-1-one  
5 (butylone, bk-MBDB e); 2-(methylamino)-1-phenylpentan-  
6 1-one (pentedrone); 1-(1,3-benzodioxol-5-yl)-2-  
7 (methylamino)pentan-1-one (pentylone, bk-MBDP); 4-  
8 fluoro-N-methylcathinone (4-FMC, flephedrone); 3-  
9 fluoro-N-methylcathinone (3-FMC); 1-(naphthalen-2-yl)-  
10 2-(pyrrolidin-1-yl)pentan-1-one (naphyrone); alpha-  
11 pyrrolidinobutiophenone ([alpha]-PBP) and their  
12 optical, positional, and geometric isomers, salts and  
13 salts of isomers, whenever the existence of such  
14 salts, isomers, and salts of isomers is possible; and  
15 [~~10~~] (13) 1-(4-methoxyphenyl)-N-methylpropan-2-amine  
16 (Other names: para-methoxymethamphetamine; PMMA)."

17 SECTION 2. Section 329-20, Hawaii Revised Statutes, is  
18 amended to read as follows:

19 "§329-20 **Schedule IV.** (a) The controlled substances  
20 listed in this section are included in schedule IV.

21 (b) Depressants. Unless specifically excepted or unless  
22 listed in another schedule, any material, compound, mixture, or

1 preparation that contains any quantity of the following  
2 substances, including its salts, isomers, esters, ethers, and  
3 salts of isomers, whenever the existence of these isomers,  
4 esters, ethers, and salts is possible within the specific  
5 chemical designation, that has a degree of danger or probable  
6 danger associated with a depressant effect on the central  
7 nervous system:

- 8 (1) Alprazolam;
- 9 (2) Barbital;
- 10 (3) Brexanolone;
- 11 (4) Bromazepam;
- 12 (5) Butorphanol;
- 13 (6) Camazepam;
- 14 (7) Carisoprodol;
- 15 (8) Chloral betaine;
- 16 (9) Chloral hydrate;
- 17 (10) Chlordiazepoxide;
- 18 (11) Clobazam;
- 19 (12) Clonazepam;
- 20 (13) Clorazepate;
- 21 (14) Clotiazepam;
- 22 (15) Cloxazolam;

- 1 (16) Daridorexant;
- 2 (17) Delorazepam;
- 3 (18) Diazepam;
- 4 (19) Dichloralphenazone (Midrin);
- 5 (20) Estazolam;
- 6 (21) Ethchlorvynol;
- 7 (22) Ethinamate;
- 8 (23) Ethyl loflazepate;
- 9 (24) Fludiazepam;
- 10 (25) Flunitrazepam;
- 11 (26) Flurazepam;
- 12 (27) Fospropofol (Lusedra);
- 13 (28) Halazepam;
- 14 (29) Haloxazolam;
- 15 (30) Ketazolam;
- 16 (31) Lemborexant ((1R,2S)-2-[(2,4-dimethylpyrimidin-5-
- 17 yl)oxymethyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-
- 18 yl)cyclopropane-1-carboxamide);
- 19 (32) Loprazolam;
- 20 (33) Lorazepam;
- 21 (34) Lormetazepam;
- 22 (35) Mebutamate;

- 1 (36) Medazepam;
- 2 (37) Meprobamate;
- 3 (38) Methohexital;
- 4 (39) Methylphenobarbital (mephobarbital);
- 5 (40) Midazolam;
- 6 (41) Nimetazepam;
- 7 (42) Nitrazepam;
- 8 (43) Nordiazepam;
- 9 (44) Oxazepam;
- 10 (45) Oxazolam;
- 11 (46) Paraldehyde;
- 12 (47) Petrichloral;
- 13 (48) Phenobarbital;
- 14 (49) Pinazepam;
- 15 (50) Prazepam;
- 16 (51) Quazepam;
- 17 (52) Remimazolam;
- 18 (53) Suvorexant;
- 19 (54) Temazepam;
- 20 (55) Tetrazepam;
- 21 (56) Triazolam;
- 22 (57) Zaleplon;

1 (58) Zolpidem; [and]

2 (59) Zopiclone (Lunesta) [-] and

3 (60) Zuranolone.

4 [~~(c)~~ Fenfluramine. Any material, compound, mixture, or

5 preparation which contains any quantity of the following

6 substances, including its salts, isomers, and salts of isomers,

7 whenever the existence of such salts, isomers, and salts of

8 isomers is possible: Fenfluramine.

9 ~~(d)~~] (c) Stimulants. Unless listed in another schedule,

10 any material, compound, mixture, or preparation which contains

11 any quantity of the following substances having a stimulant

12 effect on the central nervous system, including its salts,

13 isomers, and salts of such isomers whenever the existence of

14 such salts, isomers, and salts of isomers is possible within the

15 specific chemical designation:

16 (1) Cathine ((+)-norpseudoephedrine);

17 (2) Diethylpropion;

18 (3) Fencamfamin;

19 (4) Fenproporex;

20 (5) Lorcaserin;

21 (6) Mazindol;

22 (7) Mefenorex;

H.B. NO. 1133

- 1 (8) Modafinil;
- 2 (9) Pemoline (including organometallic complexes and
- 3 chelates thereof);
- 4 (10) Phentermine;
- 5 (11) Pipradrol;
- 6 (12) Serdexmethylphenidate;
- 7 (13) Sibutramine;
- 8 (14) Solriamfetol; and
- 9 (15) SPA (1-dimethylamino-1,2-diphenylethane, lefetamine).

10 [-(e)] (d) Other substances. Unless specifically excepted  
11 or unless listed in another schedule, any material, compound,  
12 mixture, or preparation which contains any quantity of the  
13 following substances, including its optical isomers and its  
14 salts, isomers, and salts of isomers:

- 15 (1) Pentazocine; and
- 16 (2) Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-  
17 2,6-dimethylphenyl]-1-oxopropyl] [(1S)-1-(4-phenyl-1H-  
18 imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic  
19 acid.

20 [-(f)] (e) The department of law enforcement may except by  
21 rule any compound, mixture, or preparation containing any  
22 depressant substance listed in subsection (b) or any stimulant

1 listed in subsection [~~(d)~~] (c) from the application of all or  
2 any part of this chapter if the compound, mixture, or  
3 preparation contains one or more active medicinal ingredients  
4 not having a depressant or stimulant effect on the central  
5 nervous system, and if the admixtures are included therein in  
6 combinations, quantity, proportion, or concentration that  
7 vitiate the degree of danger or probable danger of the  
8 substances which have a depressant or stimulant effect on the  
9 central nervous system.

10 [~~(g)~~] (f) Narcotic drugs. Unless specifically excepted or  
11 unless listed in another schedule, any material, compound,  
12 mixture, or preparation containing any of the following narcotic  
13 drugs, or their salts calculated as the free anhydrous base or  
14 alkaloid, in limited quantities as set forth below:

- 15 (1) Not more than one milligram of difenoxin and not less  
16 than twenty-five micrograms of atropine sulfate per  
17 dosage unit;
- 18 (2) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-  
19 diphenyl-3-methyl-2-propionoxybutane); and
- 20 (3) 2-[(dimethylamino)methyl]-1-(3-  
21 methoxyphenyl)cyclohexanol, its salts, optical and

H.B. NO. 1133

1           geometric isomers and salts of these isomers  
2           (including tramadol)."

3           SECTION 3. Statutory material to be repealed is bracketed  
4 and stricken. New statutory material is underscored.

5           SECTION 4. This Act shall take effect upon its approval.

6

7

INTRODUCED BY: *Nedra K. Parker*

8

BY REQUEST

JAN 21 2025

# H.B. NO. 1133

**Report Title:**

Uniform Controlled Substances Act

**Description:**

Updates chapter 329, HRS, to make it consistent with amendments in the Federal Controlled Substances Act as required under section 329-11, HRS.

*The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.*

## JUSTIFICATION SHEET

DEPARTMENT: Law Enforcement

TITLE: A BILL FOR AN ACT RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT.

PURPOSE: To update chapter 329, Hawaii Revised Statutes (HRS), to make it consistent with amendments in the Federal Controlled Substances Act.

MEANS: Amend sections 329-14(b), (d), and (f) and 329-20, HRS.

JUSTIFICATION: Section 329-11, HRS, requires that the Department of Law Enforcement annually recommend changes to the Hawaii Uniform Controlled Substances Act to correspond with changes to the Federal Controlled Substances Act.

Impact on the public: This bill is intended to protect the public by updating Hawaii's controlled substance schedules consistent with federal law.

Impact on the department and other agencies: These proposed amendments would assist the Department's Narcotics Enforcement Division in clarifying regulations of the Uniform Controlled Substances Act.

GENERAL FUND: None.

OTHER FUNDS: None.

PPBS PROGRAM DESIGNATION: LAW 502.

OTHER AFFECTED AGENCIES: Department of Health Food and Drug Branch; federal, state, and county law enforcement agencies.

EFFECTIVE DATE: Upon approval.